News > Federal Circuit Affirms Judgment Of Non-Infringement Involving Generic Trizivir® (Abacavir Sulfate, Lamivudine, and Zidovudine) Tablets

Federal Circuit Affirms Judgment Of Non-Infringement Involving Generic Trizivir® (Abacavir Sulfate, Lamivudine, and Zidovudine) Tablets

02/12/2015

On February 12, 2015, the U.S. Court of Appeals for the Federal Circuit affirmed the December 2013 ruling by the U.S. District Court for the District of Delaware finding that Lupin Limited’s generic abacavir sulfate, lamivudine, and zidovudine tablets product do not infringe U.S. Patent No. 6,417,191 (“the ’191 Patent”). In the litigation, ViiV Healthcare UK Ltd. and ViiV Healthcare Co. sought to prevent Lupin's marketing of a generic equivalent to Trizivir® (abacavir sulfate, lamivudine, and zidovudine). After a 4-day bench trial, the District Court concluded that Lupin's generic tablets do not infringe the '191 patent. The Federal Circuit summarily affirmed that decision.

Deanne Mazzochi, William Rakoczy, Paul Molino, and Rachel Pernic Waldron are counsel for Lupin.  Lead Counsel Deanne Mazzochi argued on behalf of Lupin before the Federal Circuit.

This victory continues to place RMMS at the forefront of generic challenges to brand pharmaceutical patents.